Enliven Therapeutics to Present at Two Upcoming Investor Conferences

BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June: Jefferies Healthcare Conference Format: Podium PresentationDate: Thursday, June 8, 2023Time: 11:00 a.m. ET The Goldman Sachs Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, June 14, 2023Time: 8:00 a.m. PT Both the presentation and fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https://ir.enliventherapeutics.com/. Each webcast will be archived for a period of 30 days following the conclusion of the live event. About Enliven Therapeutics Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer not only live longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado. Contact: Enliven Investors & Media:Argot [email protected]